In this study, we found that PD-L1+ TAMs depletion enhances the therapeutic effect of anti-PD-L1 in HCC, especially in those with GOLM1 overexpression, through neutralizing CD8+ T cell suppression and enhancing antitumor immunity. This evidence concerns the gene CD8A and hepatocellular carcinoma.